Filtered By:
Source: The Journal of Heart and Lung Transplantation
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 231 results found since Jan 2013.
Early power elevations and adverse events with the HeartMate II left ventricular assist device: An unsettled issue
In a recent issue of this journal, Salerno et al1 evaluated the prevalence and potential impact of early power elevation (PEL) events (power ≥10 W in the first 14 days after implant) on future adverse outcomes, including mortality, hemorrhagic and ischemic stroke, hemolysis and pump thrombosis, among 138 patients requiring implantation of a HeartMate II left ventricular assist device (LVAD). Patients with a PEL (20%) had similar survival, complications rates and late power elevations compared with patients without a PEL.
Source: The Journal of Heart and Lung Transplantation - September 10, 2014 Category: Transplant Surgery Authors: Omar Wever-Pinzon, Ulrich P. Jorde Tags: Case Anecdotes, Comments and Opinions Source Type: research
Inadequate Venous Return As A Primary Cause For Fontan Circulatory Limitation
The Fontan procedure is an approach to single ventricle palliation involving connection of systemic veins to the pulmonary artery(PA) without a functional sub-pulmonary pumping chamber. This is associated with chronically elevated systemic venous pressure and limited stroke volume augmentation. The latter is usually attributed to either inability to increase transpulmonary flow related to abnormal pulmonary vascular response in the absence of a sub-pulmonary ventricle or to low ventricular compliance.
Source: The Journal of Heart and Lung Transplantation - July 15, 2014 Category: Transplant Surgery Authors: Alexander R. Opotowsky, Dan Halpern, Thomas J. Kulik, David M. Systrom, Fred Wu Source Type: research
Inadequate venous return as a primary cause for Fontan circulatory limitation
The Fontan procedure is an approach to single-ventricle palliation involving the connection of systemic veins to the pulmonary artery (PA) without a functional sub-pulmonary pumping chamber. This is associated with chronically elevated systemic venous pressure and limited stroke volume augmentation. The latter is usually attributed to either inability to increase transpulmonary flow related to abnormal pulmonary vascular response in the absence of a sub-pulmonary ventricle or to low ventricular compliance.
Source: The Journal of Heart and Lung Transplantation - July 15, 2014 Category: Transplant Surgery Authors: Alexander R. Opotowsky, Dan Halpern, Thomas J. Kulik, David M. Systrom, Fred Wu Tags: Case Anecdotes, Comments and Opinions Source Type: research
Cerebrovascular disease in the era of left ventricular assist devices with continuous flow: Risk factors, diagnosis and treatment
Cerebral infarction and hemorrhage are among the principal sources of morbidity and mortality associated with mechanical circulatory support. There has been particular concern with the recently reported increased rate of device thrombosis in continuous-flow left ventricular assist devices. The neurologic management of stroke among these patients has limited data to inform current clinical practices. In this investigation we review the available literature on stroke in patients with continuous-flow left ventricular assist devices, with a focus on treatment algorithms in the acute setting and for secondary stroke prevention.
Source: The Journal of Heart and Lung Transplantation - May 31, 2014 Category: Transplant Surgery Authors: Joshua Z. Willey, Ryan T. Demmer, Hiroo Takayama, Paolo C. Colombo, Ronald M. Lazar Source Type: research
Pump size of Berlin Heart EXCOR pediatric device influences clinical outcome in children
Conclusions: The broad range of body sizes in children from newborns to adolescents requires a wide choice of appropriately sized devices. Large pump size in relation to BSA is an independent risk factor for occurrence of thromboembolic events.
Source: The Journal of Heart and Lung Transplantation - April 21, 2014 Category: Transplant Surgery Authors: Oliver Miera, Katharina R.L. Schmitt, Eva Delmo-Walter, Stanislav Ovroutski, Roland Hetzer, Felix Berger Tags: Original Clinical Science Source Type: research
Post-approval study of a highly pulsed, low-shear-rate, continuous-flow, left ventricular assist device, EVAHEART: A Japanese multicenter study using J-MACS
Conclusions: The EVAHEART device provides safe, reliable and long-term circulatory support with improved survival in commercial settings of BTT in Japan, where the transplant waiting period is much longer. Incidences of GI bleeding, hemolysis, right ventricular failure, device thrombosis and mechanical failure were extremely rare in patients on EVAHEART devices.
Source: The Journal of Heart and Lung Transplantation - March 6, 2014 Category: Transplant Surgery Authors: Satoshi Saito, Kenji Yamazaki, Tomohiro Nishinaka, Yuki Ichihara, Minoru Ono, Syunei Kyo, Takashi Nishimura, Takeshi Nakatani, Koichi Toda, Yoshiki Sawa, Ryuji Tominaga, Tadahisa Tanoue, Yoshikatsu Saiki, Yoshiro Matsui, Takahiro Takemura, Hiroshi Niinami Tags: Featured Articles Source Type: research
Early elevations in pump power with the HeartMate II left ventricular assist device do not predict late adverse events
Background: The aim of this study was to evaluate the prevalence of early pump power elevation events in patients with the HeartMate II (HMII) and its impact on subsequent development of stroke and pump thrombosis.Methods: We analyzed>45,000 measurements of pump power and pump speed measured during the initial hospitalization period and>12,000 follow-up measurements obtained from 138 consecutive patients implanted with a HMII between January 2009 and December 2012. An early power elevation (PEL) event was defined as power ≥10 W within the first 14 post-operative days. Patients were divided into two groups: those with an ...
Source: The Journal of Heart and Lung Transplantation - March 3, 2014 Category: Transplant Surgery Authors: Christopher T. Salerno, Kartik S. Sundareswaran, Thomas P. Schleeter, Sina L. Moanie, David J. Farrar, Mary Norine Walsh Tags: Featured Articles Source Type: research
Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices
Background: Continuous-flow left ventricular assist devices (LVADs) expose blood cells to high shear stress, potentially resulting in the production of microparticles that express phosphatidylserine (PS+) and promote coagulation and inflammation. In this prospective study, we attempted to determine whether PS+ microparticle levels correlate with clinical outcomes in LVAD-supported patients.Methods: We enrolled 20 patients undergoing implantation of the HeartMate II LVAD (Thoratec Corp, Pleasanton, CA) and 10 healthy controls who provided reference values for the microparticle assays. Plasma was collected before LVAD implan...
Source: The Journal of Heart and Lung Transplantation - January 21, 2014 Category: Transplant Surgery Authors: Angelo Nascimbene, Ruben Hernandez, Joggy K. George, Anita Parker, Angela L. Bergeron, Subhashree Pradhan, K. Vinod Vijayan, Andrew Civitello, Leo Simpson, Maria Nawrot, Vei-Vei Lee, Hari R. Mallidi, Reynolds M. Delgado, Jing Fei Dong, O.H. Frazier Tags: Featured Articles Source Type: research
Incidence of increases in pump power use and associated clinical outcomes with an axial continuous-flow ventricular assist device
Left ventricular assist devices (LVADs) have been shown to improve survival in patients with end-stage heart failure. Newer-generation LVADs with continuous-flow mechanics yield lower rates of disabling stroke, infection, and need for device exchange compared with earlier pulsatile-flow devices. It has been hypothesized that an elevation in the pump power may be an early indication of device thrombosis. Our goal was to define the frequency of pump power elevations, evaluate when they happen in relation to device implantation, and determine the rate at which they precede adverse events suggestive of pump thrombosis.
Source: The Journal of Heart and Lung Transplantation - January 1, 2014 Category: Transplant Surgery Authors: Robert J. Steffen, Edward G. Soltesz, Kimberly Miracle, Sangjin Lee, Maria Mountis, Nader Moazami Tags: Research Correspondence Source Type: research
Hemolysis: A harbinger of adverse outcome after left ventricular assist device implant
Background: The clinical relevance of elevated serum markers of hemolysis during left ventricular assist device (LVAD) support has not been fully ascertained.Methods: Lactate dehydrogenase (LDH) and serum free hemoglobin (sfHg) values were tallied monthly in 182 patients on HeartMate II (Thoratec, Pleasanton, CA) LVAD support. Peak values for each marker were identified, and 2 hemolysis definitions were applied to the cohort: Hemolysis according to Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) criteria (sfHg> 40 mg/dl with signs/symptoms) and/or hemolysis defined by an LDH ≥ 600 IU/liter ...
Source: The Journal of Heart and Lung Transplantation - December 2, 2013 Category: Transplant Surgery Authors: Jennifer A. Cowger, Matthew A. Romano, Palak Shah, Neha Shah, Vivek Mehta, Jonathan W. Haft, Keith D. Aaronson, Francis D. Pagani Tags: Featured Articles Source Type: research
Abnormal nutrition affects waitlist mortality in infants awaiting heart transplant
Conclusions: Moderate or severe wasting and an elevated W:H are independent risk factors for waitlist mortality in patients aged
Source: The Journal of Heart and Lung Transplantation - December 2, 2013 Category: Transplant Surgery Authors: Justin Godown, Joshua M. Friedland-Little, Robert J. Gajarski, Sunkyung Yu, Janet E. Donohue, Kurt R. Schumacher Tags: Featured Articles Source Type: research
Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation
Conclusions: LMWH in the setting of LVAD shows rapid and constant biologic efficacy. Anti-coagulation with LMWH appears feasible after LVAD implantation. These findings support further evaluation of LMWH as an alternative to unfractionated heparin in this patient cohort.
Source: The Journal of Heart and Lung Transplantation - October 28, 2013 Category: Transplant Surgery Authors: Sigrid E. Sandner, Julia Riebandt, Thomas Haberl, Stephane Mahr, Angela Rajek, Heinrich Schima, George M. Wieselthaler, Guenther Laufer, Daniel Zimpfer Tags: Featured Articles Source Type: research
Carotid-bulb thrombus and continuous-flow left ventricular assist devices: A novel observation
The continuous-flow left ventricular assist device (LVAD) has emerged as a clinically important treatment strategy for patients with advanced-stage heart failure. However, LVADs are not without associated neurologic complications, including stroke. In one review, the incidence of stroke (both ischemic and hemorrhagic) with the HeartMate II (HM II; Thoratec, Pleasanton, CA) ranged from 2% to 18%. In another recent single-center study, the incidence was 10%. In that study, previous stroke, persistent malnutrition and inflammation, severity of heart failure and post-LVAD infections were associated with neurologic complications.
Source: The Journal of Heart and Lung Transplantation - October 28, 2013 Category: Transplant Surgery Authors: John T. Reul, George J. Reul, O.H. Frazier Tags: Research Correspondence Source Type: research
Severe systemic vasospasm causing recurrent cardiac arrest after orthotopic heart transplantation
We report a case of refractory coronary and systemic vasospasm in a cardiac transplant recipient 10 years after transplantation, which ultimately required re-transplantation.
Source: The Journal of Heart and Lung Transplantation - October 17, 2013 Category: Transplant Surgery Authors: Rajiv Tayal, Janice Pieretti, David A. Baran Tags: Case Anecdotes, Comments and Opinions Source Type: research
